Indivior (NASDAQ:INDV) Now Covered by Analysts at Piper Sandler

Research analysts at Piper Sandler began coverage on shares of Indivior (NASDAQ:INDV) in a report released on Tuesday, Marketbeat.com reports. The firm set an “overweight” rating and a $22.00 price target on the stock. Piper Sandler’s price target points to a potential upside of 102.21% from the stock’s current price.

Separately, Craig Hallum dropped their target price on shares of Indivior from $37.00 to $24.00 and set a “buy” rating on the stock in a research report on Wednesday, July 10th.

Indivior Trading Down 1.3 %

Shares of INDV stock opened at $10.88 on Tuesday. The company has a debt-to-equity ratio of 23.50, a quick ratio of 0.74 and a current ratio of 0.92. The stock has a market capitalization of $1.50 billion, a P/E ratio of 1,088.00 and a beta of 0.69. The company has a 50 day moving average price of $15.26 and a 200 day moving average price of $17.69. Indivior has a fifty-two week low of $9.14 and a fifty-two week high of $24.77.

Indivior (NASDAQ:INDV) last announced its quarterly earnings data on Thursday, April 25th. The company reported $0.37 EPS for the quarter, missing analysts’ consensus estimates of $0.38 by ($0.01). Indivior had a net margin of 0.44% and a return on equity of 842.72%. The firm had revenue of $284.00 million during the quarter, compared to analysts’ expectations of $300.00 million. Equities research analysts predict that Indivior will post 1.8 EPS for the current fiscal year.

Hedge Funds Weigh In On Indivior

Large investors have recently made changes to their positions in the stock. Chilton Investment Co. Inc. purchased a new position in shares of Indivior in the 4th quarter valued at about $263,000. ADAR1 Capital Management LLC purchased a new position in Indivior during the 4th quarter valued at about $368,000. Cannon Global Investment Management LLC purchased a new position in Indivior during the 1st quarter valued at about $563,000. Campbell & CO Investment Adviser LLC increased its holdings in Indivior by 2.8% during the 4th quarter. Campbell & CO Investment Adviser LLC now owns 37,948 shares of the company’s stock valued at $573,000 after acquiring an additional 1,037 shares in the last quarter. Finally, Forsta AP Fonden purchased a new position in Indivior during the 1st quarter valued at about $641,000. Hedge funds and other institutional investors own 60.33% of the company’s stock.

About Indivior

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.